{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:46:23Z","timestamp":1792255583053,"version":"4.4.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Management of proliferative diabetic retinopathy during pregnancy requires balancing maternal vision preservation against uncertain fetal risks associated with intravitreal anti-vascular endothelial growth factor therapy. We report a 27-year-old woman with a chronic type 1 diabetes mellitus who presented at 28 weeks and 1 day of gestation with high-risk proliferative diabetic retinopathy and dense vitreous hemorrhage in the left eye, precluding panretinal photocoagulation. After multidisciplinary counseling regarding limited pregnancy safety data and treatment alternatives, a single intravitreal faricimab injection was administered at 29 weeks and 6 days of gestation. One month later, left eye visual acuity improved from counting fingers to 20\/25 with substantial clearance of the vitreous hemorrhage. Cesarean delivery was performed 37 days after injection at 36 weeks and 1 day of gestation for nonreassuring fetal heart tracings. No treatment-attributable adverse event was identified. To our knowledge, this represents the first reported use of intravitreal faricimab during pregnancy.<\/jats:p>","DOI":"10.1093\/omcr\/omag195","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:46:05Z","timestamp":1791546365000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful management of high-risk proliferative diabetic retinopathy during pregnancy with intravitreal faricimab"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3531-2301","authenticated-orcid":false,"given":"Sonia","family":"Scallon","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Loma Linda University , Loma Linda, CA 92354 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rauser","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Loma Linda University , Loma Linda, CA 92354 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-8567","authenticated-orcid":false,"given":"Anny M S","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Alaska Native Medical Center , AK 99508 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-9416","authenticated-orcid":false,"given":"Kakarla V","family":"Chalam","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Loma Linda University , Loma Linda, CA 92354 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"2026101712301582700_ref1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaophthalmol.2022.0050","article-title":"Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes","volume":"140","author":"Widyaputri","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"2026101712301582700_ref2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/IAE.0000000000003450","article-title":"panretinal photocoagulation versus intravitreal bevacizumab versus a proposed modified combination therapy for treatment of proliferative diabetic retinopathy","volume":"42","author":"Shahraki","year":"2022","journal-title":"Retina"},{"key":"2026101712301582700_ref3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/org.4.4.7415","article-title":"Role of VEGF in organogenesis","volume":"4","author":"Haigh","year":"2008","journal-title":"Role of VEGF in organogenesis. Organogenesis"},{"key":"2026101712301582700_ref4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/21556660.2020.1847926","article-title":"Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy","volume":"10","author":"Kianersi","year":"2021","journal-title":"J Drug Assess"},{"key":"2026101712301582700_ref5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41433-023-02811-6","article-title":"Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature","volume":"38","author":"Ong","year":"2024","journal-title":"Eye"},{"key":"2026101712301582700_ref6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"First Approval","volume":"82","author":"Faricimab","year":"2022","journal-title":"Drugs"},{"key":"2026101712301582700_ref7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology"},{"key":"2026101712301582700_ref8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.4239\/wjd.v12.i9.1386","article-title":"Review of the management of sight-threatening diabetic retinopathy during pregnancy. World","volume":"12","author":"Choo","year":"2021","journal-title":"J Diabetes"},{"key":"2026101712301582700_ref9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cell.2019.05.044","article-title":"Fc Glycan-Mediated Regulation of Placental Antibody Transfer","volume":"178","author":"Jennewein","year":"2019","journal-title":"Cell"},{"key":"2026101712301582700_ref10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/10\/omag195\/72066755\/omag195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/10\/omag195\/72066755\/omag195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:30:26Z","timestamp":1792254626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omag195\/8935292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,4]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omag195","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"omag195"}}